Skip to search formSkip to main contentSkip to account menu

SIB 1508Y

Known as: SIB-1508Y 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Altinicline (SIB-1508Y), an anti-Parkinson's agent, was prepared in five steps from natural nicotine in 32% overall yield via a… 
2006
2006
  • Neurology
  • 2006
  • Corpus ID: 31720763
This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective α4β2… 
Highly Cited
2000
Highly Cited
2000
Abstract.Rationale: Epidemiological studies of smokers suggest that there is a link between nicotine and depression. Nonetheless… 
Highly Cited
1999
Highly Cited
1999
Monkeys that receive chronic low-dose 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) administration have difficulty… 
Highly Cited
1998
Highly Cited
1998
The potential antiparkinsonian effects of the centrally acting, subtype‐selective neuronal nicotinic acetylcholine receptor… 
Review
1998
Review
1998
This study assessed the relative potencies of levodopa/benserazide and the nicotinic acetylcholine receptor agonist SIB‐1508Y on…